Results 1 to 10 of about 2,383,672 (201)
Some of the next articles are maybe not open access.
Targeting BTK With Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
New England Journal of Medicine, 2013Jeff P Sharman +2 more
exaly
Ibrutinib as Initial Therapy for Patients With Chronic Lymphocytic Leukemia
New England Journal of Medicine, 2015Tanya Siddiqi, Anna Schuh, Peter Hillmen
exaly
Targeting BCL2 With Venetoclax in Relapsed Chronic Lymphocytic Leukemia
New England Journal of Medicine, 2016John M Pagel +2 more
exaly
SF3B1 And Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
New England Journal of Medicine, 2011Alexander R. Vartanov +2 more
exaly
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
New England Journal of Medicine, 2018Peter Hillmen +2 more
exaly
Acute Myeloid Leukemia Management and Research in 2025
Ca-A Cancer Journal for CliniciansNaval Daver +2 more
exaly
CRISPR/Cas9 in Chronic Lymphocytic Leukemia [PDF]
Genome-editing systems such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 technology have uncovered new opportunities to model diseases such as chronic lymphocytic leukemia.
María Hernández-Sánchez
doaj +2 more sources

